GlobeNewswire

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 [...]
Clover Health Reports Third Quarter 2026 Results
04/11/2026
Business Highlights: Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth Improved Full Year 2026 guidance across all [...]
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
04/11/2026
BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced [...]
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
04/11/2026
Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at [...]
Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026
04/11/2026
Company highlights to include strategy for entering CD228V Co-development and Licensing Agreement and Proposed SkinJect® Business Combination and Concurrent Financing LOI PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- [...]
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
04/11/2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
04/11/2026
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year 3Q 2026 ASCENIV Revenue of $124.7 Million, Increasing 31% Year-over-Year 3Q 2026 GAAP Net Income of $49.9 Million, Increasing 37% Year-over-Year 3Q [...]
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
04/11/2026
Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative [...]
Pennant Reports Third Quarter 2026 Results
04/11/2026
Conference Call and Webcast scheduled for tomorrow, November 5, 2026 at 10:00 am MT EAGLE, Idaho, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
04/11/2026
-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND- [...]
electroCore Announces Third Quarter 2026 Financial Results
04/11/2026
Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 67% from [...]
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
04/11/2026
Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at [...]
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that [...]
Cytek Biosciences Reports Third Quarter 2026 Financial Results
04/11/2026
FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third [...]
Alamar Biosciences to Participate in Upcoming Investor Conferences
04/11/2026
Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be [...]
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
04/11/2026
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data [...]
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
04/11/2026
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, including the U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s [...]
Annovis Announces Launch of Proposed Public Offering
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum